HOME >> BIOLOGY >> NEWS
Critical Therapeutics launches Phase I clinical trial of anti-inflammatory compound

Cambridge, Mass., June 17, 2003 Critical Therapeutics, Inc. (CTI), a private biopharmaceutical company developing novel therapeutic products for critical care medicine, today announced the initiation of a dose-escalating Phase I clinical trial of its ethyl pyruvate compound, CTI-01.

The primary aim of the trial is to determine the safety and tolerability of the anti-inflammatory compound over a range of doses in healthy volunteer subjects. The trial will be conducted at the Clinical Pharmacology Research Unit at Parexel, Northwick Park Hospital in the United Kingdom. CTI's Phase I trial marks the first time the compound will be administered intravenously to humans.

"This study encompasses the achievement of several milestones," said CTI President and CEO Paul Rubin, M.D. "It marks CTI's first clinical trial in the Company's brief history and is especially notable because CTI-01 was discovered by Mitch Fink M.D., one of the company's founders. The speed and efficiency which with which we have advanced CTI-01 into human trials reflects the dedication and initiative of our entire team."

CTI-01 is a cytoprotective compound that reduces vascular and organ damage following severe insults to the body such as surgical and non-surgical trauma, pancreatitis or overwhelming infection. The small molecule has demonstrated potent anti-inflammatory and tissue protection activity in multiple animal treatment models of disease including pancreatitis, vascular reperfusion injury, hepatitis and endotoxemia. CTI-01 has the potential to prevent and reverse complications in patients undergoing serious operations or multi-organ failure associated with life- threatening acute conditions including shock, myocardial infarction, acute pancreatitis, burns, stroke or acute drug allergies.

Approximately $180 billion is spent each year to treat patients with these life threatening conditions, according to a study conducted by researchers at the Universit
'"/>

Contact: Scott Solomon
ssolomon@investorrelations.com
617-542-5300
Sharon Merrill Associates, Inc.
17-Jun-2003


Page: 1 2

Related biology news :

1. Critically endangered monkey species plummets more than 50 percent since 1994
2. Save The Tiger Fund announces alliance with the Critical Ecosystem Partnership Fund
3. Critical Therapeutics announces issuance of US patent for novel anti-inflammatory technology
4. Medimmune and Critical Therapeutics to co-develop treatments for severe inflammatory diseases
5. Critical early-defense trigger in plants found
6. Critical therapeutics is awarded U.S. patents for methods to diagnose and treat inflammatory disease
7. Researchers, Regulators, Industry, Consumer Advocates Gather to Discuss Critical Issues Facing the Pharmaceutical Industry
8. Study Furthers Understanding Of Critical Alzheimers Disease Gene
9. Gene Once Thought To Program Ovarian Development Instead Found To Be Critical For Production Of Sperm
10. UF Researchers: Gene Therapy Replaces Critical Protein In Animal Model Of Often-Fatal Lung-Liver Disease
11. Columbia Researchers Synthesize Compound With Possible Link To MacularDegeneration; Work Is Critical To Pinpointing Causes Of Disease, Scientists Say

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/4/2019)... ... 02, 2019 , ... Stay on top of current hot topics through free ... to all webinars is free, so be sure to register today to save your ... http://www.xtalks.com to see our upcoming webinars: , CLINICAL OPERATIONS , August 27 – ...
(Date:8/1/2019)... ... July 31, 2019 , ... Molecular ... launch of the next generation of its FLIPR® Penta High-Throughput Cellular Screening System. ... FLIPR® platform for monitoring of G-protein-coupled receptors (GPCRs) and ion channels, offering a ...
(Date:7/24/2019)... ... July 24, 2019 , ... NDA Partners Chairman Carl ... with more than 20 years of experience working in scientific research and FDA-regulated ... as an Expert Consultant. , Dr. Hartzfeld has experience in all aspects of ...
Breaking Biology News(10 mins):
(Date:6/11/2019)... ... June 10, 2019 , ... ... add 80 of its scientific journals to DeepDyve’s rental service for peer-reviewed journals. ... continually expanding library of more than 20 million articles, sourced from more than ...
(Date:6/11/2019)... DURHAM, N.C. (PRWEB) , ... June 11, 2019 ... ... how extracellular vesicles derived from human mesenchymal stem cells (MSC-EV) are able to ... and cloning ability. In a test on mice, MSC-EVs also increased the cells’ ...
(Date:5/31/2019)... ... May 29, 2019 , ... ... from the USPTO providing proprietary interest to our methodology, processes, and diagnostic ... DIAGNOSIS AND TREATMENT… extends Somnology’s IP rights including our proprietary sleep scoring ...
(Date:5/31/2019)... ... May 30, 2019 , ... A study released today ... system for the sustained release of human placental stem cell (HPSC)-derived conditioned medium ... to deliver CM into the injured kidney, where it helped restore function and ...
Breaking Biology Technology:
Cached News: